Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season

Figures & data

Figure 1. Relative frequency histogram of log₂ serum VNTs of the exploratory study (black bars) and the FIH vaccine trial (open bars).

Figure 2. Cumulative relative frequency distribution of log₂ serum VNTs of the exploratory study (black curve) and the FIH vaccine trial (gray curve). Dotted line marks the 54% of subjects in both studies with a VNT ≤ 9.9 log_2.

Table 1. Serum virus neutralization titer per month.

		Serum virus neutralization titer (log2)
Month	Sample size (n)	Mean (SD)	Range
April	13	9.9 (1.4)	7.0–11.4
May	40	10.2 (1.3)	7.3–12.0
June	17	10.2 (1.2)	7.9–12.0
July	46	10.1 (1.4)	6.4–12.0
Augustus	50	9.4 (1.0)	7.5–11.7
September	24	9.9 (1.3)	7.1–10.4